A traditional Chinese medicine composition for treating bronchiectasis combined with airflow limitation

Abstract

The present invention relates to the field of disease treatment, and in particular to a Chinese medicine composition for treating bronchiectasis combined with airflow limitation. The Chinese medicine composition is composed of the following Chinese medicinal materials: 5-20 parts by weight of perilla seeds, 5-25 parts by weight of scutellaria seeds, 8-30 parts by weight of raw astragalus, 5-20 parts by weight of atractylodes, 5-20 parts by weight of pinellia tuber, 5-20 parts by weight of tangerine peel, 8-3 parts by weight of houttuynia cordata, 15-20 parts by weight of platycodon grandiflorum, and 5-20 parts by weight of aster. The Chinese medicine composition can effectively reduce qi and asthma, improve airway stenosis, tonify the lungs and invigorate the spleen, eliminate the source of phlegm, eliminate phlegm and pus, and help sputum discharge, effectively alleviating the cough, expectoration, and dyspnea symptoms of bronchiectasis patients, and improving the severity of airflow limitation. Since its actual clinical application, no adverse events have occurred.

Description

Technical Field

[0001] The present invention relates to the field of throat disease treatment, and in particular to a traditional Chinese medicine composition for treating bronchiectasis combined with airflow limitation. Background Art

[0002] Bronchiectasis (BE) is a common structural lung disease characterized by recurrent suppurative infections caused by various factors, resulting in repeated damage and / or obstruction of the small and medium-sized airways, structural damage to the bronchial walls, and abnormal and persistent bronchial dilation. Clinically, it presents as persistent or recurrent cough and sputum production, sometimes accompanied by hemoptysis. Bronchiectasis is a long-lasting and irreversible disease. Repeated infections, particularly extensive bronchiectasis, can severely damage lung tissue and function, leading to respiratory dysfunction and chronic cor pulmonale, severely impacting patients' quality of life and imposing a heavy socioeconomic burden.

[0003] Over 80% of patients with bronchiectasis experience decreased lung function and airflow limitation. In addition to clinical symptoms such as cough and sputum production, these patients also experience wheezing, shortness of breath, and dyspnea. It is currently believed that the severity of airflow limitation increases year by year as bronchiectasis progresses and the disease worsens. Patients with bronchiectasis and airflow limitation often experience higher levels of airway inflammation, frequent acute exacerbations, and poorer quality of life and prognosis. Therefore, improving airflow limitation is a crucial component of long-term treatment for patients with bronchiectasis. Currently, Western medicine has significantly insufficient attention to this issue. Clinical guidelines / consensuses in many countries lack clear treatment options. In clinical practice, inhaled medications are often used, often based on treatments for conditions such as chronic obstructive pulmonary disease (COPD) or asthma, but satisfactory results remain. Traditional Chinese medicine (TCM) offers significant advantages in treating bronchiectasis. Lung and spleen qi deficiency and phlegm-heat accumulation in the lungs are the most common syndromes in patients with bronchiectasis and airflow limitation. For these patients, reducing qi and relieving asthma by improving airway narrowing, tonifying the lungs and spleen to eliminate the source of phlegm production, and promoting expectoration and pus removal can effectively alleviate cough, sputum production, and dyspnea, and improve the severity of airflow limitation in patients with bronchiectasis. The following products are currently on the market:

[0004] Qingke Pingchuan Granules: Clears heat and promotes lung function, relieves cough and asthma. Used for acute bronchitis and acute exacerbations of chronic bronchitis characterized by phlegm-heat stagnation in the lungs. Symptoms include cough, shortness of breath, or even wheezing, yellow or unpleasant sputum, fever, sore throat, dry stool, and a yellow or greasy tongue coating.

[0005] Xuanfei Pingchuan Granules: Dispel lung heat, resolve phlegm, relieve cough, and alleviate asthma. It dispels lung heat, relieves cough, and alleviates asthma. It is used for asthma and lung heat accumulation. Symptoms include wheezing, cough, and shortness of breath; thick, yellow sputum or blood in sputum; chest discomfort or fever; flushed face; thirst and preference for cold drinks; dark urine; or constipation. The tongue is red, with a yellow or greasy coating; and the pulse is stringy or slippery. It is used for patients with bronchial asthma, chronic obstructive pulmonary disease, and acute bronchitis who also experience these symptoms. Summary of the Invention

[0006] In summary, the present invention provides a traditional Chinese medicine composition for treating bronchiectasis with airflow limitation. The composition can effectively alleviate acute and chronic bronchiectasis with airflow limitation, has minimal side effects, and has been used clinically without any adverse events.

[0007] Specifically, the technical solution of the present invention is achieved as follows:

[0008] A traditional Chinese medicine composition for treating bronchiectasis combined with airflow limitation, comprising the following traditional Chinese medicines: 5-20 parts by weight of perilla seeds, 5-25 parts by weight of scutellaria seeds, 8-30 parts by weight of raw astragalus, 5-20 parts by weight of atractylodes, 5-20 parts by weight of pinellia, 5-20 parts by weight of tangerine peel, 8-30 parts by weight of houttuynia cordata, 15-20 parts by weight of platycodon grandiflorum, and 5-20 parts by weight of aster.

[0009] Furthermore, the traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 12 parts by weight of perilla seed, 12 parts by weight of scutellaria seed, 15 parts by weight of raw astragalus, 12 parts by weight of atractylodes, 12 parts by weight of pinellia, 12 parts by weight of tangerine peel, 15 parts by weight of houttuynia cordata, 12 parts by weight of platycodon grandiflorum, and 12 parts by weight of aster.

[0010] In one embodiment of the present invention, the traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 5 parts by weight of perilla seed, 5 parts by weight of scutellaria seed, 8 parts by weight of raw astragalus, 5 parts by weight of atractylodes, 5 parts by weight of pinellia, 5 parts by weight of tangerine peel, 8 parts by weight of houttuynia cordata, 15 parts by weight of platycodon grandiflorum, and 5 parts by weight of aster.

[0011] In one embodiment of the present invention, the traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 20 parts by weight of perilla seed, 25 parts by weight of scutellaria seed, 8-30 parts by weight of raw astragalus, 20 parts by weight of atractylodes, 20 parts by weight of pinellia, 20 parts by weight of tangerine peel, 3 parts by weight of houttuynia cordata, 20 parts by weight of platycodon grandiflorum, and 20 parts by weight of aster.

[0012] The second object of the present invention is to provide a use of a traditional Chinese medicine composition in the preparation of a medicament for treating bronchiectasis combined with airflow limitation. Furthermore, the bronchiectasis combined with airflow limitation refers to patients with bronchiectasis combined with airflow limitation.

[0013] A third object of the present invention is to provide a Chinese medicine preparation containing the Chinese medicine composition of the present invention, wherein the Chinese medicine preparation is an oral solid preparation and / or an oral liquid preparation. The oral solid preparation is one of a tablet, a capsule, a pill, and a granule. The oral liquid preparation is one of a decoction, an oral liquid, a syrup, and a mixture.

[0014] The third object of the present invention is to provide a preparation process of the composition as follows:

[0015] The Chinese medicinal materials of the present invention are soaked in water for 20-40 minutes, then decocted twice, with the first decoction time being 60-80 minutes and the second decoction time being 10-30 minutes, filtered, and the two filtrates are collected to obtain a decoction.

[0016] Compared with the prior art, the present invention has achieved remarkable results:

[0017] The Chinese medicine composition of the present invention has the synergistic effect of the effective ingredients of various Chinese medicines so that the efficacy can be fully exerted and maximized in a short time. This prescription has all the monarch, minister, assistant and envoy ingredients, and the compatibility is rigorous. The scutellaria baicalensis can purge the lungs and lower the qi, eliminate phlegm and relieve asthma, while the perilla seed can lower the qi and eliminate phlegm, relieve cough and relieve asthma. The two are based on the meaning of Su Ting Ding Chuan Pills, and the cold and warm properties mutually restrain each other to eliminate phlegm and stop asthma, and they are both monarch medicines; raw astragalus is the best tonic, a holy medicine for invigorating qi, which can nourish the lungs and spleen, and astragalus can also discharge pus and support the interior, and is a holy medicine for sores and carbuncles, so it is the minister medicine; Atractylodes lancea can dry dampness and strengthen the spleen and has the effect of eliminating phlegm. Xu Shuwei recorded in "Puji Benshi Fang" that Atractylodes lancea was used to remove cysts, and it is recognized A cyst is caused by spleen deficiency and poor function, leading to the accumulation of phlegm and fluid over time. Bronchiectasis patients experience hypersecretion of mucus in their airways, making phlegm difficult to expel, similar to a cyst. Therefore, Atractylodes macrocephala is used to dry the spleen and overcome dampness, while Soil and Earth are used to fill the mortar to dissipate the dampness. Pinellia ternata awakens the spleen, dries dampness, and resolves phlegm, while Tangerine peel strengthens the spleen, dries dampness, and resolves phlegm. Adding Atractylodes macrocephala enhances this function. Together with Astragalus membranaceus, these herbs serve as assistant herbs, strengthening the lung and spleen qi and preventing the growth of phlegm. As Zhang Jingyue said, "The only way to effectively treat phlegm is to prevent it from forming; this is the hand that mends the sky." Platycodon grandiflorum clears the lungs, eliminates phlegm, and pus; Houttuynia cordata clears the lungs and eliminates pus; and Aster tataricus eliminates phlegm and relieves cough, all serving as adjuvant herbs. The entire formula combines lung-tonifying and spleen-strengthening, clearing heat and resolving phlegm, and descending qi to relieve asthma.

[0018] The Chinese medicine composition can effectively reduce gas and asthma, improve airway stenosis, nourish the lungs and strengthen the spleen to eliminate the source of phlegm, eliminate phlegm and pus and help sputum discharge, which can effectively alleviate the cough, sputum and dyspnea symptoms of patients with bronchiectasis and improve the severity of airflow limitation. Since its actual clinical application, no adverse events have occurred. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 : Trend chart of changes in mMRC scores of patients in the experimental group and the control group during clinical treatment.

[0020] Figure 2 : CAT score change trend chart of patients in the experimental group and the control group during clinical treatment.

[0021] Figure 3 : Trend chart of cough symptom scores changes in the experimental group and the control group during clinical treatment.

[0022] Figure 4 : Trend chart of changes in sputum cough symptom scores of patients in the experimental group and the control group during clinical treatment.

[0023] Figure 5 : 24-hour sputum volume change trend chart of patients in the experimental group and the control group during clinical treatment. DETAILED DESCRIPTION

[0024] The following describes a method for treating bronchiectasis combined with airflow limitation according to the present invention in conjunction with some specific embodiments. The specific examples are for further illustrating the present invention in detail, but do not limit the scope of protection of the present invention.

[0025] 1. Clinical trial data of embodiments of the present invention

[0026] 1.1 General Information

[0027] This team conducted a randomized, double-blind, placebo-controlled study between March and December 2022 to investigate the efficacy of the Sufei Pingchuan formula in treating airflow limitation in patients with bronchiectasis. There were no statistically significant differences in gender, age, and condition between the two groups (P>0.05), indicating comparability.

[0028] 1.2 Inclusion criteria:

[0029] (1) The diagnostic criteria for bronchiectasis were developed with reference to the Expert Consensus on the Diagnosis and Treatment of Bronchiectasis in Adults (2012 Edition) developed by the Expert Consensus on the Diagnosis and Treatment of Bronchiectasis in Adults group: High-resolution chest CT is the primary means of diagnosing bronchiectasis. The criteria were determined based on a comprehensive analysis of medical history, clinical manifestations, physical signs, and laboratory tests. Stable period criteria: The patient had no fever, no hemoptysis, no wheezing, or other systemic symptoms. Acute exacerbation criteria: The patient experienced worsening symptoms, i.e., cough, increased sputum volume or changes in nature, increased purulent sputum, and / or wheezing, shortness of breath, hemoptysis, and fever. PA colonization: Pseudomonas aeruginosa was found in sputum culture within the past 3 months.

[0030] (2) Diagnostic criteria for TCM syndrome types

[0031] The guidelines are based on the "Guidelines for the Diagnosis and Treatment of Common Diseases in Traditional Chinese Medicine Internal Medicine - TCM Symptoms" published by the China Association of Traditional Chinese Medicine in 2008: cough, spitting up purulent sputum, greenish-blue sputum, shortness of breath, fatigue, poor appetite, spontaneous sweating, sallow complexion, red or pale red tongue, thin or greasy fur, and a wiry or slippery pulse.

[0032] Case inclusion criteria

[0033] (1) Patients who meet the diagnostic criteria for PA colonization bronchiectasis;

[0034] (2) Age 18–70 years old;

[0035] (3) Patients diagnosed by TCM as having lung and spleen deficiency and phlegm-heat accumulation in the lungs;

[0036] (4) patients who had at least one acute exacerbation in the past year;

[0037] (5) Those who are willing to follow the doctor's diagnosis and treatment arrangements and sign the informed consent form.

[0038] Case exclusion criteria

[0039] (1) Those who do not meet the above-mentioned Western medicine diagnosis and TCM syndrome differentiation standards:

[0040] (2) Pregnant or breastfeeding women

[0041] (3) history of chronic alcoholism or drug abuse or any factors that affect compliance; (4) poor compliance during the screening period;

[0042] (5) Combined with primary diseases of cardiovascular, cerebrovascular, liver, kidney and hematopoietic systems;

[0043] (6) Abnormal liver and kidney function: liver function indicators (such as ALT or AST) exceeding the upper limit of normal values ​​by more than one times or abnormal kidney function, such as abnormal BUN or Cr;

[0044] (7) Psychiatric patients;

[0045] (8) Those with allergic constitution or allergic to this drug;

[0046] (9) Those who have used other similar drugs for treatment;

[0047] (10) Participated in other clinical treatments within 1 month.

[0048] Research Methods

[0049] The experimental group was orally administered the decoction prepared in Example 1, one dose per day. The drug was discontinued after 24 weeks of treatment.

[0050] Control group: Azithromycin tablets (0.25 g / tablet, National Medical Products Administration Approval No. H10960167, Pfizer Inc.), 0.5 g per dose, every other day, orally. The drug was discontinued after 24 weeks of treatment.

[0051] Finally, the efficacy of each group of patients was evaluated, and the results were statistically analyzed to evaluate the efficacy.

[0052] 1.5 Observation indicators

[0053] 1.5.1 Criteria for determining efficacy:

[0054] It was formulated with reference to the "Guiding Principles for Clinical Research of New Chinese Medicines" published by China Medical Science and Technology Press in 2002 and the "Standards for Diagnosis and Efficacy of Traditional Chinese Medicine Diseases" issued by the State Administration of Traditional Chinese Medicine.

[0055] Clinical recovery: Symptoms disappear after treatment, and symptom scores are reduced by >95%.

[0056] Markedly effective: After treatment, the total symptom score is reduced by >70% and <95%.

[0057] Effective: After treatment, the total symptom score is reduced by >30% and <70%.

[0058] Ineffective: Symptoms did not improve or worsened after treatment, and the total score decreased by <30%.

[0059] Note: The calculation formula (nimodipine method) is [(score before treatment - score after treatment) / score before treatment] * 100%.

[0060] 1.5.2 Comparison of lung function

[0061] The changes of lung function before and after treatment in each group were compared: forced expiratory volume in 1 second as a percentage of predicted value FEV1%pred, and FEV1 / FVC in one second; the changes of lung function before and after treatment in the two groups were compared and statistical analysis was performed.

[0062] 1.5.3 Inflammatory indicators

[0063] The changes of blood inflammatory markers (CRP, ESR) before and after treatment were compared and statistically analyzed.

[0064] 1.5.4 Sputum culture

[0065] 1.6 Statistical methods

[0066] Normally distributed measurement data were analyzed using t-tests and paired t-tests; those not normally distributed were analyzed using rank sum tests and other methods. Enumeration data were analyzed using chi-square tests and other methods. Statistical significance was determined when the P value was less than 0.05.

[0067] 1.7 Results

[0068] The results showed that Sufei Pingchuan prescription can improve lung function, dyspnea severity (mMRC score), quality of life score (CAT score), cough, sputum and dyspnea symptoms, reduce 24-hour sputum volume, reduce airway inflammation and mucin levels in patients with stable bronchiectasis (lung and spleen qi deficiency, phlegm-heat accumulation in the lungs), as shown in Table 1-2 and Figure 1-5 .

[0069] Table 1 Comparison of lung function between the two groups (L, (x ± s;%, (x ± s)

[0070]

[0071] Table 2 Comparison of inflammatory and mucin indicators in sputum supernatant of two groups of patients (pg / mL, M(P25, P75))

[0072]

[0073] 2. Experimental Example: Effect of Drugs on Croton Oil-Induced Rabbit Vocal Cord Inflammation

[0074] 2.1 Experimental Animals and Drugs

[0075] Animals: 45 ordinary-grade New Zealand rabbits, half male and half female, weighing 2.2 ± 0.25 kg, were provided by the Experimental Animal Center of Xiyuan Hospital, China Academy of Chinese Medical Sciences (Animal No.: SYXK(Beijing)2023-0053, Jiangsu Province Laboratory Animal Certificate No. 97001).

[0076] Experimental drugs: model group (normal saline), dexamethasone acetate cream (positive control group), decoctions of Examples 1-3, and decoctions of Comparative Examples 1-6.

[0077] Compared with the model group, each of the example groups and the positive control group had a significant inhibitory effect on the croton oil-induced vocal cord inflammation in rabbits. Examples 1-3 showed extremely significant differences compared with comparative examples 1-6, with statistical significance (P < 0.01). Example 1 was superior to Examples 2-3, with statistical significance (P < 0.05). Further, the composition of the present invention has a significant therapeutic effect.

[0078] 3. Preparation of the Chinese medicine composition of the present invention

[0079] Example 1: A decoction for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0080] Perilla seed 12g, scutellaria seed 12g, raw astragalus 15g, atractylodes 12g, pinellia 12g, tangerine peel 12g, houttuynia cordata 15g, platycodon 12g, aster 12g.

[0081] Preparation process: Take the Chinese medicinal materials of the present invention, soak them in water for 20-40 minutes, then decoct them twice, the first decoction time is 60-80 minutes, the second decoction time is 10-30 minutes, filter, and collect the two filtrates to obtain a decoction.

[0082] Example 2: A decoction for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0083] Perilla seed 5g, scutellaria seed 5g, raw astragalus 8g, atractylodes 5g, French pinellia 5g, tangerine peel 5g, houttuynia cordata 8g, platycodon 15g, aster 5g.

[0084] The preparation process is the same as that of Example 1.

[0085] Example 3: A decoction for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0086] Perilla seed 20g, scutellaria seed 25g, raw astragalus 8-30g, atractylodes 20g, pinellia 20g, tangerine peel 20g, houttuynia cordata 3g, platycodon 20g, aster 20g.

[0087] The preparation process is the same as that of Example 1.

[0088] Example 4: A granule for treating bronchiectasis combined with airflow limitation, the formulation and preparation thereof are as follows:

[0089] Perilla seed 12g, scutellaria seed 12g, raw astragalus 15g, atractylodes 12g, pinellia 12g, tangerine peel 12g, houttuynia cordata 15g, platycodon 12g, aster 12g.

[0090] The above 9 herbs are prepared by soaking the Chinese medicinal materials described in the present invention in water for 20-40 min, then decocting them twice, with the first decoction lasting 60-80 min and the second decoction lasting 10-30 min. The mixture is filtered, and the filtrates are collected and concentrated to a clear paste with a relative density of 1.15-1.35 (at 60-65° C.). β-cyclodextrin and sucrose are added, and the mixture is granulated in a fluidized bed and dried to obtain granules.

[0091] The preparation process is the same as that of Example 1.

[0092] Comparative Example 1: A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0093] Perilla seed 12g, scutellaria seed 12g, raw astragalus 15g, atractylodes 12g, pinellia 12g, tangerine peel 12g, houttuynia cordata 15g, platycodon 12g, aster 12g.

[0094] The preparation process is the same as that of Example 1.

[0095] Comparative Example 2: A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0096] Perilla seed 25g, scutellaria seed 3g, raw astragalus 10g, atractylodes 10g, French pinellia 22g, tangerine peel 2g, houttuynia cordata 5g, platycodon 25g, aster 3g.

[0097] The preparation process is the same as that of Example 1.

[0098] Comparative Example 3: A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0099] Raw Astragalus 27g, Atractylodes 12g, Pinellia 12g, Tangerine Peel 12g, Houttuynia Cordata 27g, Platycodon 12g, Aster 12g.

[0100] The preparation process is the same as that of Example 1.

[0101] Comparative Example 4: A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0102] Perilla seed 27g, scutellaria seed 27g, Atractylodes lancea 12g, Pinellia ternata 12g, Tangerine peel 12g, Platycodon grandiflorum 12g, Aster tataricus 12g.

[0103] The preparation process is the same as that of Example 1.

[0104] Comparative Example 5: A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0105] Panax notoginseng 12g, scutellaria baicalensis seeds 12g, raw astragalus 15g, atractylodes 12g, pinellia 12g, tangerine peel 12g, houttuynia cordata 15g, liquorice 12g, aster 12g.

[0106] The preparation process is the same as that of Example 1.

[0107] Comparative Example 6: A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, the prescription and preparation of which are as follows:

[0108] Element Content (g) Ginseng 15 Ophiopogon japonicus 20 Plantago ovata 15 Wooden Butterfly 10 Licorice 12 lily 20

[0109] Preparation process:

[0110] Take ginseng, ophiopogon, sterculia lychnophora, oroxylum, licorice and lily, soak them in water for 20-40 minutes, then boil them for 60-80 minutes, filter and collect the filtrate, boil the residue in water for 10-30 minutes, filter and collect the filtrate twice to obtain a decoction.

Claims

1. A Chinese medicine composition for treating bronchiectasis combined with airflow limitation, characterized in that: The traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 5-20 parts by weight of perilla seeds, 5-25 parts by weight of scutellaria seeds, 8-30 parts by weight of raw astragalus, 5-20 parts by weight of atractylodes, 5-20 parts by weight of pinellia, 5-20 parts by weight of tangerine peel, 8-30 parts by weight of houttuynia cordata, 15-20 parts by weight of platycodon grandiflorum, and 5-20 parts by weight of aster.

2. The Chinese medicine composition according to claim 1, wherein The traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 12 parts by weight of perilla seeds, 12 parts by weight of scutellaria seeds, 15 parts by weight of raw astragalus, 12 parts by weight of atractylodes, 12 parts by weight of pinellia, 12 parts by weight of tangerine peel, 15 parts by weight of houttuynia cordata, 12 parts by weight of platycodon grandiflorum, and 12 parts by weight of aster.

3. The Chinese medicine composition according to claim 1, wherein The traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 5 parts by weight of perilla seeds, 5 parts by weight of scutellaria seeds, 8 parts by weight of raw astragalus, 5 parts by weight of atractylodes, 5 parts by weight of pinellia, 5 parts by weight of tangerine peel, 8 parts by weight of houttuynia cordata, 15 parts by weight of platycodon grandiflorum, and 5 parts by weight of aster.

4. The Chinese medicine composition according to claim 1, wherein The traditional Chinese medicine composition is composed of the following traditional Chinese medicines: 20 parts by weight of perilla seeds, 25 parts by weight of scutellaria seeds, 8-30 parts by weight of raw astragalus, 20 parts by weight of atractylodes, 20 parts by weight of pinellia, 20 parts by weight of tangerine peel, 3 parts by weight of houttuynia cordata, 20 parts by weight of platycodon grandiflorum, and 20 parts by weight of aster.

5. Use of the traditional Chinese medicine composition according to any one of claims 1 to 4 in the preparation of a medicament for treating bronchiectasis combined with airflow limitation.

6. The use according to claim 5, characterized in that The bronchiectasis combined with airflow limitation is a symptom of bronchiectasis accompanied by airflow limitation.

7. A Chinese medicine preparation, characterized in that The traditional Chinese medicine preparation is prepared from the traditional Chinese medicine composition according to any one of claims 1 to 4.

8. The Chinese medicine preparation according to claim 7, characterized in that The traditional Chinese medicine preparation is an oral solid preparation or an oral liquid preparation.

9. The Chinese medicine preparation according to claim 8, characterized in that The oral solid preparation is one of tablets, capsules, pills and granules.

10. The Chinese medicine preparation according to claim 8, characterized in that The oral liquid preparation is one of decoction, oral liquid, syrup and mixture.

Images